Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF

Neoplasia

Volumn 6, Issue 6, 2004, Pages 846-853

  El Sheikh, Soha Salama ^a   Domin, Jan ^a   Abel, Paul ^a   Stamp, Gordon ^a   Lalani, El Nasir ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Akt; EGF; MAPK; PI3K; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RELIABILITY; SIGNAL TRANSDUCTION;

EID: 11144292081     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04379     Document Type: Article

References (45)

1. Barton J, Blackledge G, and Wakeling A (2001). Growth factors and their receptors: new targets for prostate cancer therapy. Urology 58, 114-122.
2. George DJ (2002). Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology 60, 115-121 discussion, 122.
3. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, and Kung HJ (1997). ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 15, 2705-2716.
4. Kim HG, Kassis J, Souto JC, Turner T, and Wells A (1999). EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histol Histopathol 14, 1175-1182.
5. Bargmann CI, Hung MC, and Weinberg RA (1986). Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649-657.
6. Kraus MH, Issing W, Miki T, Popescu NC, and Aaronson SA (1989). Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86, 9193-9197.
7. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, and Shoyab M (1993). Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90, 1746-1750.
8. Carraway KL III and Cantley LC III (1994). A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78, 5-8.
9. Vanhaesebroeck B and Waterfield MD (1999). Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253, 239-254.
10. Prigent SA and Gullick WJ (1994). Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 13, 2831-2841.
11. Arcaro A, Zvelebil MJ, Wallasch C, Ullrich A, Waterfield MD, and Domin J (2000). Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol Cell Biol 20, 3817-3830.
12. Wheeler M and Domin J (2001). Recruitment of the class II phosphoinositide 3-kinase C2beta to the epidermal growth factor receptor: role of Grb2. Mol Cell Biol 21, 6660-6667.
13. Datta SR, Brunet A, and Greenberg ME (1999). Cellular survival: a play in three Akts. Genes Dev 13, 2905-2927.
14. Cantley LC and Neel BG (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96, 4240-4245.
15. Brognard J, Clark AS, Ni Y, and Dennis PA (2001). Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer Res 61, 3986-3997.
16. Itoh N, Semba S, Ito M, Takeda H, Kawata S, and Yamakawa M (2002). Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94, 3127-3134.
17. Reddy KB, Nabha SM, and Atanaskova N (2003). Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22, 395-403.
18. Cobb MH, Hepler JE, Cheng M, and Robbins D (1994). The mitogen-activated protein kinases, ERK1 and ERK2. Semin Cancer Biol 5, 261-268.
19. Price DT, Rocca GD, Guo C, Ballo MS, Schwinn DA, and Luttrell LM (1999). Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 162, 1537-1542.
20. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, and Narayan P (1995). Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 31, 14-24.
21. Cussenot O, Berthon P, Berger R, Mowszowicz I, Faille A, Hojman F, Teillac P, Le Duc A, and Calvo F (1991). Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. J Urol 146, 881-886.
22. Degeorges A, Hoffschir F, Cussenot O, Gauville C, Le Duc A, Dutrillaux B, and Calvo F (1995). Recurrent cytogenetic alterations of prostate carcinoma and amplification of c-myc or epidermal growth factor receptor in subclones of immortalized PNT1 human prostate epithelial cell line. Int J Cancer 62, 724-731.
23. Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, and Jacobberger JW (1999). A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35, 403-409.
24. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, and Sandberg AA (1980). The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37, 115-132.
25. Stone KR, Mickey DD, Wunderli H, Mickey GH, and Paulson DF (1978). Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21, 274-281.
26. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, and Jones LW (1979). Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17, 16-23.
27. Domin J, Gaidarov I, Smith ME, Keen JH, and Waterfield MD (2000). The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in clathrin-coated vesicles. J Biol Chem 275, 11943-11950.
28. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rogers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, and Parsons R (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.
29. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, and Trapman J (1998). Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58, 2720-2723.
30. She Q-B, Solit D, Basso A, and Moasser MM (2003). Resistance to Gefitinib in PTEN-Null HER-Overexpressing tumor cells can be overcome through restoration of PTEN Function or pharmacologic modulation of Constitutive Phosphatidylinositol 3′-Kinase/Akt pathway Signaling. Clin Cancer Res 9, 4340-4346.
31. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Uberall F, and Klocker H (1999). Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59, 227-233.
32. Arai Y, Yoshiki T, and Yoshida O (1997). c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate 30, 195-201.
33. De Miguel P, Royuela N, Bethencourt R, Ruiz A, Fraile B, and Paniagua R (1999). Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 11, 722-727.
34. Fossa A, Lilleby W, Fossa SD, Gaudernack G, Torlakovic G, and Berner A (2002). Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int J Cancer 99, 100-105.
35. Kumar VL, Majumder PK, Gujral S, and Kumar V (1998). Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate. Cancer Lett 134, 177-180.
36. Savinainen KJ, Saramaki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, and Visakorpi T (2002). Expression and Gene Copy Number Analysis of ERBB2 Oncogene in Prostate Cancer. Am J Pathol 160, 339-345.
37. Watanabe M, Nakada T, and Yuta H (1999). Analysis of protooncogene c-erbB-2 in benign and malignant human prostate. Int Urol Nephrol 31, 61-73.
38. Hayward SW, Wang Y, Cao M, Horn YK, Zhang B, Grossfeld GD, Sudilovsky D, and Cunha GR (2001). Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 61, 8135-8142.
39. Mitchell S, Abel P, Ware M, Stamp G, and Lalani E (2000). Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int 85, 932-944.
40. Connolly JM and Rose DP (1991). Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 19, 173-180.
41. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM (1991). Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 51, 2780-2785.
42. MacDonald A, Chisholm GD, and Habib FK (1990). Production and response of a human prostatic cancer line to transforming growth factor-like molecules. Br J Cancer 62, 579-584.
43. Freeburn RW, Wright KL, Burgess SJ, Astoul E, Cantrell DA, and Ward SG (2002). Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors. J Immunol 169, 5441-5450.
44. Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsert LM, Moodie D, and Stokoe D (2000). 5′ phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol 20, 6860-6871.
45. Walker SM, Downes CP, and Leslie NR (2001). TPIP: a novel phosphoinositide 3-phosphatase. Biochem J 360, 277-283.